

LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

Bictegravir Resistance

Cabotgravir Resistance

EXAMPLE, REPORT W

WX0000003826 F 12/05/1988 35 Y

Referral Testing						
	Collected: 0	8/13/202	4 15:13	Received:	08/13/2024	15:13
<u>Test Name</u>	Result	<u>Flag</u>	Ref-Ranges	<u>Uı</u>	<u>nits</u>	<u>Site</u>
HIV-1 Integrase Genotype						
Value of Last Viral Load	12					QCRL
Date of Load Collected	1/13/2024					QCRL
Raltegravir Resistance	NOT PREDICTED					QCRL
Elvitegravir Resistance	NOT PREDICTED					QCRL
Dolutegravir Resistance	NOT PREDICTED					QCRL

NOT PREDICTED

NOT PREDICTED

The Quest Diagnostics September 2021 Interpretation Algorithm

The method used in this test is RT-PCR and sequencing of the HIV-1 integrase gene. The phrases 'resistance predicted' and 'probable or emerging resistance' refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at:
Quest Diagnostics Infectious Disease, Inc.
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 H J Batterman MD

Reported Date: 08/13/2024 15:14 HVIGE

Performing Site:

QCRL

OCRI

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

G413000044 WX0000003826 Printed D&T: 08/13/24 15:14 Ordered By: KAJAL SITWALA, MD, PHD WX00000000002353